RedDrop Dx Secures $5 Million Series Seed to Expand At-Home and Automation-Ready Blood Collection Platform
RedDrop Dx, the Fort Collins, Colorado–based medical device company innovating at‑home and automation‑ready blood collection technology, has closed an oversubscribed $5 million Series Seed funding round, securing capital to scale manufacturing, expand commercial partnerships, and enhance its platform for decentralized clinical trials and remote diagnostics. The investment marks a critical step as digital health and telehealth services increasingly demand scalable, patient‑centric diagnostics infrastructure that moves beyond traditional phlebotomy.
The seed round was led by Innosphere Ventures, a Colorado‑based venture capital and startup incubator firm focused on early‑stage technology and life sciences enterprises. Innosphere’s participation underscores strong confidence in RedDrop Dx’s ability to transform one of healthcare’s most persistent bottlenecks — blood sample collection — by combining virtually painless sampling with full compatibility for high‑volume laboratory automation workflows.
Joining Innosphere Ventures as lead capital providers was Stout Street Capital, an investment firm that backs early‑stage companies across healthcare, technology, and consumer sectors. Stout Street Capital’s support reflects the market’s broader interest in technologies that enable decentralized care delivery and streamline diagnostic processes. Additionally, the funding round included participation from Breakthrough Venture Capital, a firm known for supporting frontier technologies. Collectively, these investors bring both industry expertise and financial backing that are expected to help accelerate RedDrop Dx’s growth as it moves into its next phase of commercialization and scale.
Since its founding in 2019 by CEO Kris Buchanan, RedDrop Dx has focused on developing devices that remove the barriers traditionally associated with blood draws. Its flagship product, RedDrop ONE, received FDA 510(k) clearance in 2024, validating it as a Class II medical device to collect up to one milliliter of capillary blood painlessly at home or point of care. The device is designed to deliver clinical‑grade samples directly into automation‑ready tubes that integrate seamlessly into existing high‑throughput laboratory workflows — a critical advantage for telehealth providers, decentralized clinical trial organizations, and commercial laboratories seeking to scale services.
RedDrop Dx’s platform addresses a persistent pain point in diagnostics: phlebotomy appointments are often uncomfortable, inconvenient, and a barrier to timely patient testing. By enabling individuals to self‑collect blood with minimal discomfort and without trained professionals, RedDrop Dx allows healthcare providers and labs to offer more accessible and frequent testing. This shift is especially relevant for chronic disease monitoring, population health initiatives, and decentralized trials where frequent sample collection can be essential but logistically challenging.
The newly raised funding will be deployed to expand manufacturing capacity to meet the growing demand for RedDrop ONE devices, widen strategic partnerships, and advance product development. RedDrop Dx plans to use the capital to refine its hardware and software systems, increase production throughput, and build relationships with telehealth and laboratory partners that can bring its technology into broader use. The company’s strategy aligns with a broader healthcare trend toward patient‑centric and decentralized care models, where diagnostic testing can occur outside traditional clinical settings and closer to where people live and work.
RedDrop Dx has already begun forming commercial relationships that highlight the practical utility of its technology. For example, partnerships have been announced with key laboratory services providers to integrate RedDrop ONE into at‑home hormone and other diagnostic test kits, demonstrating the device’s flexibility across healthcare applications and its potential to expand remote testing offerings.
As the healthcare industry continues to embrace digital transformation, solutions like RedDrop Dx’s are increasingly seen as foundational infrastructure for decentralized diagnostics. The company’s approach — combining intuitive device design with compatibility for laboratory automation — aims to reduce operational friction and improve patient experience, offering a compelling value proposition for providers, laboratories, and patients alike.
With its $5 million seed round now closed, RedDrop Dx is positioned to accelerate its mission of making blood collection more accessible, scalable, and integrated into modern healthcare workflows. Backed by investors with deep expertise in early‑stage technology deployment, the company is well‑placed to expand its footprint in telehealth, clinical trials, and decentralized care environments. As demand for remote diagnostics grows, RedDrop Dx’s funded roadmap could help shape how blood collection and testing are conducted in the future, bringing patient‑centric diagnostic solutions to a broader population.
